A world-class specialty biopharmaceutical company

Our ambition is to become a leading specialty biopharmaceutical company meeting the needs of patients around the world. With our market-leading asthma management products and development pipeline of treatments for allergy, asthma and COPD we’re making good progress towards achieving our goal.

Our technologies

We’re using our proprietary technologies to develop short-course treatments for allergy and a range of therapies for asthma and chronic obstructive pulmonary disease (COPD).

Our products

Our novel NIOX® products are used to assist asthma diagnosis, direct treatment and help with ongoing monitoring.

Our pipeline

We’re developing a broad range of products and our lead asthma treatment was recently approved in the UK.

About us

We’re a world-class specialty biopharmaceutical company focused on allergy, asthma and COPD.

Careers

We’re a rapidly growing company with a range of exciting career opportunities.

Investors

Circassia is listed on the London Stock Exchange under the ticker CIR.

Press Releases

More press releases

Share Price

Full share price chart

Annual Report

Read the Annual Report (PDF)